
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication was paid for by and developed under the direction of Bayer. It was not peer reviewed. Financial support and promotional content direction were provided by members of Bayer Market Access team.
This AJMC® Clinical Brief describes ways in which payers can optimize management of patients with chronic kidney disease associated with type 2 diabetes.






